Cullinan Therapeutics Inc. recently provided an update on their ongoing research and development efforts at the ASCO 2025 event, focusing on Zipalertinib. The presentation highlighted the REZILIENT1 results overview, strategic perspectives, and next steps for the treatment of EGFR ex20ins NSCLC. Key speakers included Nadim Ahmed, Jeff Jones, MD, MBA, and Danny Nguyen, MD. The company also discussed its ongoing clinical programs, including CLN-049 for AML & MDS and CLN-617 for solid tumors, emphasizing their potential in various therapeutic areas. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cullinan Therapeutics Inc. published the original content used to generate this news brief on June 02, 2025, and is solely responsible for the information contained therein.